Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cantor Fitzgerald Reiterates Overweight on Oncolytics Biotech, Maintains C$9 Price Target

Author: Benzinga Newsdesk | May 17, 2023 09:47am
Cantor Fitzgerald analyst Louise Chen reiterates Oncolytics Biotech (TSX:ONC) with a Overweight and maintains C$9 price target.

Posted In: TSX:ONC